# Laurie H. Sehn

Source: https://onco.cc/people/laurie-sehn/  
OnCo record `laurie-sehn` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Lymphoma specialist who wrote the definitive DLBCL review and helped establish polatuzumab and other new agents.

## Summary

Laurie Sehn developed the revised International Prognostic Index for the rituximab era, led the BC Cancer population-based studies that showed R-CHOP's real-world impact, and was a lead investigator of the GO29365 trial establishing polatuzumab vedotin in relapsed DLBCL and of POLARIX. She authored the 2021 NEJM review of DLBCL and chairs lymphoma care in British Columbia.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: lymphoma; canada; outcomes
- Role: Chair, Lymphoma Tumour Group, BC Cancer; Clinical Professor, University of British Columbia
- Specialisms: Diffuse large B-cell lymphoma; Population-based outcomes; Novel agents; Prognostic indices

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Sehn%20LH%5BAuthor%5D%20diffuse%20large%20B-cell%20lymphoma

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [CD20](https://onco.cc/targets/cd20/)
- institutions: [BC Cancer](https://onco.cc/institutions/bc-cancer/)
- trials: [GOYA](https://onco.cc/trials/goya/), [POLARIX](https://onco.cc/trials/polarix/)
- key papers: [Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma](https://onco.cc/key-papers/paper-goya-obinutuzumab-vs-rituximab-chop-dlbcl-jco-2017/), [Randomized phase III trial of ibrutinib and R-CHOP in non-germinal centre B-cell diffuse large B-cell lymphoma (PHOENIX)](https://onco.cc/key-papers/paper-phoenix-ibrutinib-r-chop-non-gcb-dlbcl-jco-2019/), [Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial](https://onco.cc/key-papers/paper-inmind-tafasitamab-lenalidomide-rituximab-follicular-lancet-2026/)
- roadmaps: [Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting](https://onco.cc/roadmaps/lymphoma-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/laurie-sehn.json